With its eyes set on an IPO raise, In­Car­da un­rolls mid-stage da­ta back­ing in­haled ar­rhyth­mia drug

Work­ing to craft an old ar­ry­th­mia drug in­to a more user-friend­ly in­haled for­mu­la­tion, In­Car­da is ex­pect­ing to use new Phase II da­ta re­vealed Wednes­day as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER